drugset / Trial / NCT04914377
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested positive for novel Coronavirus 2019 (Covid-19) in the outpatient setting. Patients will be treated at a dose of 500 mg, 3 capsules, two times a day for 14 days from date of randomization. Quantitative viral load as measured by RT-PCR will be evaluated at baseline and on days 7 and 14. Covid-19 symptoms will be measured throughout the study using Modified FLU-PRO Plus.
Timeline
- Start
- 2021-06-08
- Primary completion
- 2021-12-16
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQ Formula | Unknown | 3 g | Oral |